All News

2018

July

Media Release / Jul 19, 2018

Novartis demonstrates commitment to lead immuno-dermatology by in-licensing IL-17C compound for atopic dermatitis

Read More
Media Release / Jul 18, 2018

Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women

Read More
Media Release / Jul 18, 2018

Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company

Read More
Areal view Novartis
Featured News / Jul 18, 2018

Novartis Financial Results – Q2 2018

Today, Novartis announced the company’s financial results for the second quarter and H1 of 2018.

Read More
Featured News / Jul 13, 2018

Essential Consultants – Updates

Read More
Dr. Luca Finelli demonstrates to his team members the interface of the predictive module Sense on a screen.
Story / Jul 02, 2018

Drug development gets big data analytics boost

With Nerve Live, Novartis is harnessing the power of data for the benefit of patients.

Read More

June

Media Release / Jun 29, 2018

Novartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe

Read More
Media Release / Jun 29, 2018

Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn

Read More
Media Release / Jun 28, 2018

Novartis presents new data demonstrating long-term efficacy, safety and tolerability of Aimovig® (erenumab) in patients with chronic and episodic migraine

Read More
Media Release / Jun 27, 2018

Novartis International AG: Global study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month

Read More

Pages

Related Links

Annual Report 2017

Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.

Learn More